Date: Tuesday, November 30, 2021
Time: 8:00 am – 9:00 am PST / 11:00 am – 12:00 pm EST
Speakers: Prof. Stefan Russmann & Dr. Robin Everts

Sponsored by Agena Bioscience^®

Evidence for the impact of pharmacogenetic factors on drug effects has markedly increased in recent years. However, the inclusion of pharmacogenetics in prescription decisions in clinical practice lags the initial high expectations for this new field of clinical pharmacology.

This webinar will address the strengths and limitations of pharmacogenetics for modern pharmacotherapy. Prof. Stefan Russmann, clinical pharmacologist and pharmacoepidemiologist, will discuss the latest scientific evidence supporting pharmacogenetics-guided pharmacotherapy, share his first-hand experience with implementing pharmacogenetics in clinical practice, and provide an overview of how pharmacogenetics may change drug development and prescription in the future.

Prof. Russmann will cover drug-drug-gene interactions, the implementation and benefits of pharmacogenetic panel testing, CYP2C19 and clopidogrel therapy, CYP2D6 and tamoxifen therapy, and DPYD and chemotherapy. In addition, Dr. Robin Everts from Agena Bioscience will follow with an overview of Agena’s MassARRAY^® System and the latest developments in DPYD testing.

Prof. Stefan Russmann
Stefan Russmann is a clinical pharmacologist and founder of drugsafety.ch. He is a senior consulting physician at Hirslanden Hospital Group in Switzerland, a professor of clinical pharmacology and toxicology at the University of Zurich, and an alumni professor of epidemiology at Boston University. Russmann is the current vice-president of the Swiss ISoP chapter as well as a member of the Swiss Society of Pharmacology and Toxicology, Section of Clinical Pharmacology (SGKPT), and the German Society of Pharmacology and Toxicology, Section of Clinical Pharmacology (DGPT).

Dr. Robin Everts
Robin Everts trained as a molecular geneticist and has published 48 peer-reviewed articles in different fields including gene expression in immunology, developmental biology, pharmacogenetics, and gene mapping. He has, for the last 10 to 15 years, focused primarily on improving and expanding the pharmacogenetics and clinical genetics capabilities of the Agena Bioscience MassARRAY Analyzer platform. Some of the products he conceived are the ADME PGx Pro Panel, the VeriDose Core Panel, and the VeriDose CYP2D6 CNV panel, as well as panels for CFTR and Ashkenazi Jewish gene mutations. He is a member of AMP, CPIC, PGRN, and CLSI. He is also a contributor to the CDC’s Genetic Testing Reference Materials Coordination Program.